Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Invested Capital (2020 - 2025)

Historic Invested Capital for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $724.7 million.

  • Maravai Lifesciences Holdings' Invested Capital fell 3611.9% to $724.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $724.7 million, marking a year-over-year decrease of 3611.9%. This contributed to the annual value of $873.1 million for FY2024, which is 3355.25% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Invested Capital of $724.7 million as of Q3 2025, which was down 3611.9% from $761.9 million recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Invested Capital peaked at $1.4 billion during Q4 2022, and registered a low of $724.7 million during Q3 2025.
  • For the 5-year period, Maravai Lifesciences Holdings' Invested Capital averaged around $1.1 billion, with its median value being $1.2 billion (2022).
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Invested Capital skyrocketed by 5931.16% in 2022, and later plummeted by 4116.96% in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Invested Capital (Quarter) stood at $1.1 billion in 2021, then skyrocketed by 33.15% to $1.4 billion in 2022, then fell by 8.28% to $1.3 billion in 2023, then tumbled by 33.55% to $873.1 million in 2024, then decreased by 17.0% to $724.7 million in 2025.
  • Its last three reported values are $724.7 million in Q3 2025, $761.9 million for Q2 2025, and $825.2 million during Q1 2025.